Experience with intrauterine transfusions for severe Rh alloimmunization in a developing country.
This study reports our experience with 67 intrauterine transfusions (IUTs) carried out for 27 cases of severe Rh alloimmunization, which could be useful to other developing countries with similar situations. Most of the mothers were from sections of India other than Mumbai, their socioeconomic status was low, and they were referred during the second or third trimester. The mean gestation age at first IUT was 27+/-2.9 weeks and maternal anti-D titer ranged from 1:32 to 1:512. Ultrasonography (USG) was normal in eight cases, but showed minimal or gross ascites in 8 and 11 cases, respectively. The mean +/- SD hematocrit (HCT) in three groups defined by USG was 23.5+/-1.7, 15.9+/-4, and 12+/-5.9, respectively. Amniotic fluid analysis, which proved to be an important investigation, indicated IUT in eight cases having normal USG. Six cases were severely anemic (Hb deficit >7 g/dl). By fetal cell staining, the percentage of the donor's red cells in the fetal circulation was determined. Besides Hb, blood group, direct antiglobulin test, and mean cell volume, this parameter was also useful in assessing efficacy of IUT and the need for an exchange transfusion after birth. Of 11 fetuses having gross ascites, eight and one each from the remaining two groups, were stillborn. One death may be procedure related. Two neonates died due to hemorrhagic disorder and prematurity. The overall survival rate was 55.6%. Late referral, severe Rh alloimmunization, volume overload, delay in IUT because of nonavailability of blood and use of nonirradiated blood could be the reasons for the poor outcome. Strategies for improving results are discussed.
Gupte
S C
SC
Institute of Immunohaematology, Indian Council of Medical Research, Parel, Mumbai. dir@icmriih.ren.nic.in
Lulla
C P
CP
Kulkarni
S S
SS
Korgaonkar
S A
SA
Walvekar
V R
VR
Merchant
R H
RH
D001805:Blood Transfusion, Intrauterine / Q000379:methods; D003906:Developing Countries; D004899:Erythroblastosis, Fetal / Q000628:therapy; D005260:Female; D005313:Fetal Death / Q000209:etiology; D005865:Gestational Age; D006801:Humans; D007194:India; D007231:Infant, Newborn; D007518:Isoantibodies / Q000097:blood; D011247:Pregnancy; D012203:Rh Isoimmunization / Q000150:complications / Q000628:therapy*; D012204:Rh-Hr Blood-Group System / Q000276:immunology
D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System